1) major depression
重症抑郁症
1.
Relationship between cognitive function and anxiety in patients with major depression;
重症抑郁症病人认知功能与焦虑的关系
3) Major depression
重性抑郁症
1.
The Study of Personality among Different Stages of Major Depression;
重性抑郁症患者不同病期人格特征研究
2.
Association Analysis between the Norepinephrine Transporter Gene, Social Psychic Factors, Their Interaction and Major Depression;
NET基因、社会心理因素及其交互作用与重性抑郁症的关联研究
3.
Objective:Using neuropsychological tests to assess the cognitive functions of major depression(MD)and analyze the relationship between the cognitive impairment and the alternation of serum cortisol level.
目的 :探讨重性抑郁症患者神经心理学和皮质醇浓度的相关性。
4) major depressive disorder
重度抑郁症
1.
Objective:To investigate the attentional bias for negative emotional facial expressions in major depressive disorder(MDD).
目的:探讨重度抑郁症患者对负性情绪面孔的注意偏向。
2.
MethodsThe study consisted of 82 Chinese Han inpatients diagnosed as major depressive disorder.
对符合美国精神疾病分类标准第4版(DSM-Ⅳ)诊断标准,无严重躯体疾病;无药物或酒依赖史,既往无躁狂或轻躁狂发作史,2004年5月—2005年3月期间到中国医科大学门诊就诊的重度抑郁症患者82例为研究对象,给予抗抑郁药物治疗(氟。
5) first episode major depression
首发重性抑郁症
1.
1H-MRS in frontal lobe and hippocampus of patients with first episode major depression;
首发重性抑郁症患者双侧额叶和海马的磁共振质子波谱成像
2.
~1H-MRS in bilaterlis frontal lobe and hippocampus of patients with first episode major depression after SSRIs antidepressant treatment;
SSRIs抗抑郁药治疗首发重性抑郁症患者前后双侧额叶和海马~1H-MRS的分析
6) major depression disorder(MDD)
重症抑郁性障碍
1.
Desvenlafaxine succinate,produced by Wyethpharms Inc,is approved by the US FDA for the treatment of major depression disorder(MDD).
琥珀酸去甲文拉法辛(desvenlafaxine succinate,商品名为Pristiq)于2008年2月29日经美国FDA批准上市,由美国Wyethpharms inc公司生产,用于治疗重症抑郁性障碍(MDD)。
补充资料：抑郁等位症
抑郁等位症
见"抑郁症"。
说明：补充资料仅用于学习参考，请勿用于其它任何用途。
参考词条